NCT02262728View on ClinicalTrials.gov

An Efficacy, Safety and Pharmacokinetics Study of Simeprevir, Daclatasvir and Sofosbuvir in Participants With Chronic Hepatitis C Virus Genotype 1 or 4 Infection and Decompensated Liver Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

August 13, 2015

Study Completion Date

April 25, 2018

Conditions
Hepatitis C, Chronic
Interventions
DRUG

Simeprevir

Simeprevir 150 milligram (mg) capsule orally once daily for 12 weeks

DRUG

Daclatasvir

Daclatasvir 60 mg tablet orally once daily for 12 weeks

DRUG

Sofosbuvir

Sofosbuvir 400 mg tablet orally once daily for 12 weeks

Trial Locations (1)

Unknown

San Antonio

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT02262728 - An Efficacy, Safety and Pharmacokinetics Study of Simeprevir, Daclatasvir and Sofosbuvir in Participants With Chronic Hepatitis C Virus Genotype 1 or 4 Infection and Decompensated Liver Disease | Biotech Hunter | Biotech Hunter